Kate E. Rogers

509 total citations
14 papers, 384 citations indexed

About

Kate E. Rogers is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Kate E. Rogers has authored 14 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Medicine, 11 papers in Pharmacology and 4 papers in Epidemiology. Recurrent topics in Kate E. Rogers's work include Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Pneumonia and Respiratory Infections (4 papers). Kate E. Rogers is often cited by papers focused on Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Pneumonia and Respiratory Infections (4 papers). Kate E. Rogers collaborates with scholars based in Australia, United States and Spain. Kate E. Rogers's co-authors include Jürgen B. Bulitta, Lauren C. Binge, Charles R. Mackay, Laurence Macia, Angélica T. Vieira, Jan Kranich, Eliana Mariño, Cornelia B. Landersdorfer, Alison N. Thorburn and Kendle M. Maslowski and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Immunological Reviews and Clinical Pharmacology & Therapeutics.

In The Last Decade

Kate E. Rogers

14 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kate E. Rogers Australia 10 168 160 143 75 56 14 384
Yuan Lv China 10 75 0.4× 269 1.7× 131 0.9× 75 1.0× 41 0.7× 33 443
Yanfei Wang China 14 79 0.5× 315 2.0× 166 1.2× 104 1.4× 15 0.3× 33 595
Ahmad Alhajhusain United States 9 38 0.2× 157 1.0× 126 0.9× 95 1.3× 29 0.5× 21 389
B. Kemmerich Germany 14 199 1.2× 125 0.8× 68 0.5× 118 1.6× 27 0.5× 29 513
Dimitris Goukos Greece 10 277 1.6× 426 2.7× 99 0.7× 242 3.2× 141 2.5× 15 694
Jennifer Villa Spain 15 106 0.6× 389 2.4× 187 1.3× 149 2.0× 121 2.2× 30 666
Jinyao Sun China 14 193 1.1× 127 0.8× 86 0.6× 114 1.5× 47 0.8× 18 478
Meg Kays United States 9 115 0.7× 97 0.6× 153 1.1× 65 0.9× 23 0.4× 16 396
Ana María Sánchez‐Díaz Spain 9 110 0.7× 99 0.6× 97 0.7× 209 2.8× 49 0.9× 25 397

Countries citing papers authored by Kate E. Rogers

Since Specialization
Citations

This map shows the geographic impact of Kate E. Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate E. Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate E. Rogers more than expected).

Fields of papers citing papers by Kate E. Rogers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate E. Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate E. Rogers. The network helps show where Kate E. Rogers may publish in the future.

Co-authorship network of co-authors of Kate E. Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Kate E. Rogers. A scholar is included among the top collaborators of Kate E. Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate E. Rogers. Kate E. Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Cortés-Lara, Sara, Kate E. Rogers, Carla López-Causapé, et al.. (2024). The effects of single and multiple resistance mechanisms on bacterial response to meropenem. Clinical Microbiology and Infection. 30(10). 1276–1283. 1 indexed citations
2.
Agyeman, Akosua Adom, Carla López-Causapé, Kate E. Rogers, et al.. (2023). Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity. International Journal of Antimicrobial Agents. 62(3). 106887–106887. 10 indexed citations
3.
Harper, Marina, Sara Cortés-Lara, Kate E. Rogers, et al.. (2023). Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrobial Agents and Chemotherapy. 67(8). e0041423–e0041423. 4 indexed citations
4.
5.
Barnett, Timothy C., Kate E. Rogers, Wee Leng Lee, et al.. (2022). Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling. Journal of Antimicrobial Chemotherapy. 77(7). 1923–1930. 1 indexed citations
6.
Agyeman, Akosua Adom, Kate E. Rogers, Phillip J. Bergen, et al.. (2021). Evaluation of Meropenem‐Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. Clinical Pharmacology & Therapeutics. 109(4). 1104–1115. 15 indexed citations
7.
Yadav, Rajbharan, Phillip J. Bergen, Kate E. Rogers, et al.. (2019). Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. Antimicrobial Agents and Chemotherapy. 64(1). 19 indexed citations
8.
Yadav, Rajbharan, Kate E. Rogers, Jürgen B. Bulitta, et al.. (2018). Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy. 62(11). 31 indexed citations
9.
Landersdorfer, Cornelia B., Rajbharan Yadav, Kate E. Rogers, et al.. (2018). Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. Antimicrobial Agents and Chemotherapy. 62(4). 9 indexed citations
10.
11.
Landersdorfer, Cornelia B., Rajbharan Yadav, Kate E. Rogers, et al.. (2018). Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy. 62(4). 32 indexed citations
12.
Bergen, Phillip J., Jürgen B. Bulitta, Carl M. J. Kirkpatrick, et al.. (2017). Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy. 61(5). 33 indexed citations
13.
Bergen, Phillip J., Jürgen B. Bulitta, Carl M. J. Kirkpatrick, et al.. (2016). Effect of different renal function on antibacterial effects of piperacillin againstPseudomonas aeruginosaevaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy. 71(9). 2509–2520. 33 indexed citations
14.
Macia, Laurence, Alison N. Thorburn, Lauren C. Binge, et al.. (2011). Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunological Reviews. 245(1). 164–176. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuan Lv Breakdown of academic impact, for papers by Yanfei Wang Breakdown of academic impact, for papers by Ahmad Alhajhusain Breakdown of academic impact, for papers by B. Kemmerich Breakdown of academic impact, for papers by Dimitris Goukos Breakdown of academic impact, for papers by Jennifer Villa Breakdown of academic impact, for papers by Jinyao Sun Breakdown of academic impact, for papers by Meg Kays Breakdown of academic impact, for papers by Ana María Sánchez‐Díaz
Rankless by CCL
2026